

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7286703

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PIQUR THERAPEUTICS	01/29/2021
RECEIVING PARTY DATA	
Name:	TORQUR AG
Street Address:	RITTERGASSE 3
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	4051
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16045427
CORRESPONDENCE DATA	
Fax Number:	(703)712-8525
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(703) 712-8531
Email:	admin@medlerferro.com, docketing@medlerferro.com
Correspondent Name:	MEDLER FERRO WOODHOUSE & MILLS PLLC
Address Line 1:	8201 GREENSBORO DRIVE
Address Line 2:	SUITE 1060
Address Line 4:	MCLEAN, VIRGINIA 22102
ATTORNEY DOCKET NUMBER:	P3135US01 (0192-0015US2)
NAME OF SUBMITTER:	CYNTHIA M. BOUCHEZ
SIGNATURE:	/Cynthia M. Bouchez/
DATE SIGNED:	04/19/2022
Total Attachments: 2	
source=P3135US01 (0192-0015US2) - Assignment - Piquir to Torqur#page1.tif	
source=P3135US01 (0192-0015US2) - Assignment - Piquir to Torqur#page2.tif	

ASSIGNMENT

In consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned **PIQUR THERAPEUTICS AG** (the Assignor) hereby sells and assigns to **TORQUR AG** (the Assignee), a corporation having a principle place of business at Rittergasse 3, Basel 4051, Switzerland, their entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **NOVEL MANUFACTURING PROCESS FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES** for which application for patent in the United States of America was filed on **July 25, 2018**, also known as United States Application No. **16/045,427**, now **United States Patent No. 10,766,874**, issued **September 8, 2020**, in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, international applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions and discoveries described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned agrees to execute all papers necessary in connection with the applications and any non-provisional, international, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned agrees to execute all papers necessary in connection with any derivation or patent enforcement action (judicial or otherwise) related to the applications or


any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.


The undersigned hereby represents that he has full right to convey the entire interest herein assigned, and that he has not executed, and will not execute, any agreement in conflict therewith.

The undersigned hereby grants the attorneys associated with Customer Number 56719 power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned on the date opposite his name.

Date: 29 January 2021

Signature of Representative: 
Richard LAUBE, Chairman of the Board of Directors
PIQUR THERAPEUTICS AG
Hochbergerstr. 60C
4057 Basel, Switzerland

Signature of Representative: 
Christian SALZ, Member of the Board of Directors
PIQUR THERAPEUTICS AG
Hochbergerstr. 60C
4057 Basel, Switzerland